Global TRK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 Drugs
- Approved TRK Drug Patent, Price & Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
https://www.kuickresearch.com/report-trk-inhibitors-market-size-sales-growth-forecast
Tropomyosin receptor kinase A, B, and C (TRKA, TRKB, and TRKC) are well known members of the cell surface receptor tyrosine kinases which are encoded by NTRK1, NTRK2, and NTRK3 respectively. The TRK have shown to regulate cell proliferation, differentiation, and even apoptosis through various downstream signaling pathways including MAPK, P13K/AKT, and PLC-y. Further, researchers have also demonstrated that the alterations in these genes are associated with the prevalence of several cancers including breast, colorectal, non-small cell lung cancer and other solid tumors. Hence, TRK emerged as a potential target for the development of novel drugs in the management of cancer.
Lorlatrectinib was the first TRK inhibitor which was approved by FDA in 2018 for the management of NTRK positive solid tumors. The drug is sold under the brand name Vitrakvi and was developed by Loxo Oncology. Later in 2019, Rozlytrek developed by Roche was also approved for the management of NTRK positive solid tumors as well as non-small cell lung cancer. Both these drugs are first generation TRK inhibitor and have shown potent activity against wild-type TRKA, TRKB, and TRKC. Currently, the market is mainly dominated by Vitrakvi, which is mainly due to its robust sales and the availability of the drug at a global level.
Several ongoing studies are also evaluating the role of approved TRK inhibitors in the management of other cancers including non-small cell lung cancer, glioblastoma, colorectal cancer, and other hematological malignancies. For instance, Vitrakvi currently present in phase-II for the management of acute leukemia. Apart from this, TRK inhibitors are also being evaluated in combination with chemotherapy regimen or immunotherapeutic drugs to enhance their efficiency in targeting the cancer cells. The extended approval of these drugs in other conditions as well as in combination with other drugs will propel the growth of market.
Despite several favorable parameters, the market will be mainly restricted by the onset of drug resistance in patients and the side effects on central nervous system. To tackle this, researchers are currently developing several second generation TRK inhibitors which have shown to overcome the resistance to first generation TRK inhibitors. The major candidates in the pipeline are Selitectinib, Repotrectinib, VMD928, CHC2014, ICP723, and Taletrectinib. The majority of these drugs are present in phase-II, which suggests that they will enter the market in next 3-5 years.
It has only been few years since the entry of TRK inhibitors into the market and in such a short period of time, it has emerged out to be successful therapy for the entire cancer therapeutics market, as it targets the disease at a molecular level. Apart from this, major biopharmaceutical companies around the world have initiated several strategic alliances which will foster the growth in the global market with launches of large number of products in forthcoming years. The high prevalence of cancer and the unavailability of effectively curing drugs will also increase the demand of TRK inhibitors in near future. As per our analysis, the global TRK inhibitor market is expected to grow to US$ 2 Billion by 2026.
US will account for more than 60% in the global market and is expected to maintain its dominance during the forecast period. Several factors including presence of large pharmaceutical sector which actively invest in research and development activities as well as increasing funding by the government to promote research and development have contributed in the growth of TRK inhibitors in the region. In addition to this, the rise in prevalence of cancer and the increase awareness for the acceptance of novel therapies is also going to drive the future of the market.
Contact:
Neeraj Chawla
Research Head
+91-9810410366